Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...

As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.

Scientists have developed a single-dose treatment for breast cancer that eliminates small tumors and significantly shrinks ...

We have yet to find the cure for cancer, but there are ways to treat the disease and mitigate your risk of dying from it - ...

The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...

A Montana fitness-based business owner faces jail time for illegally selling bodybuilding drugs that fight "man boobs." He pleaded guilty to selling ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

While pericytes are important regulators of capillary function and homeostasis, the lack of specific markers has hampered the ...

Ductal carcinoma in situ is a precursor of breast cancer that is usually treated with surgery, radiation therapy, and ...

Tyler J. Hall pleaded guilty to introducing unapproved drugs into interstate commerce, a violation of federal law that requires FDA approval to sell the chemicals for human consumption.

New University of Cincinnati Cancer Center research has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.

Medically reviewed by Gagandeep Brar, MDInflammatory breast cancer (IBC) is an uncommon and aggressive type of breast cancer.